Comparable stake leader
Erkki Ruoslahti
SEC ownership of LISATA THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000320017.
Disclosed value leader
Erkki Ruoslahti
Comparable rows
0/50
Latest evidence
31 Mar 2026
- Symbol
- LSTA on Nasdaq
- SEC evidence covered
- 3/4/5 and 13F
- Largest SEC-reported holder
- Erkki Ruoslahti
- Latest parsed evidence date
- 31 Mar 2026
- CIK
- 0000320017
- Location
- Basking Ridge, NJ
Ownership snapshot
1 signal
Issuer
2 identity fields
Ownership snapshot
Top shareholders of LISATA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Erkki Ruoslahti
Disclosed value leader
Erkki Ruoslahti
Comparable rows
0/50
Latest evidence
31 Mar 2026
3/4/5
13F
Highest disclosed value: $3,561,521
50 rows are not safely comparable across share classes.
Showing 1-8 of 50 holder rows.
Quick read
Erkki Ruoslahti has the largest disclosed position value at $3.56M.
0 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Disclosed position value
Top 5
Erkki Ruoslahti
$3.56M
VANGUARD CAPITAL MANAGEMENT LLC
$1.36M
Steven S. Myers
$668.1K
RENAISSANCE TECHNOLOGIES LLC
$659.9K
Michael H. Davidson
$627.2K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Erkki Ruoslahti |
3/4/5
Director
|
—
class O/S missing
|
$3,561,521
1,191,144 shares
|
— | 09 Jan 2023 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$1,361,793
271,815 shares
|
— | 31 Mar 2026 |
| Steven S. Myers |
3/4/5
Director
|
—
class O/S missing
|
$668,142
223,459 shares
|
— | 10 Jan 2022 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
class O/S missing
|
$659,892
131,715 shares
|
— | 31 Mar 2026 |
| Michael H. Davidson |
3/4/5
Director
|
—
class O/S missing
|
$627,161
209,753 shares
|
— | 10 Jan 2022 |
| David J. Mazzo |
3/4/5
President & CEO, Director
|
—
mixed-class rows
|
$614,423
351,890 shares
mixed-class rows
|
— | 09 Jan 2026 |
| Anne Clem Whitaker |
3/4/5
Director
|
—
class O/S missing
|
$546,079
182,635 shares
|
— | 10 Jan 2022 |
| Todd C. Girolamo |
3/4/5
CLO, SVP of Corp Dev
|
—
class O/S missing
|
$480,873
160,827 shares
|
— | 13 Jan 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to LISATA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Erkki Ruoslahti
Net 12M change
$0
Latest report
09 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Erkki Ruoslahti | Director | $3,561,521 | Mixed | 09 Jan 2023 | ||
| Steven S. Myers | Director | $668,142 | Mixed | 10 Jan 2022 | ||
| Michael H. Davidson | Director | $627,161 | Mixed | 10 Jan 2022 | ||
| David J. Mazzo | President & CEO, Director | $614,423 | Mixed | 09 Jan 2026 | ||
| Anne Clem Whitaker | Director | $546,079 | Mixed | 10 Jan 2022 | ||
| Todd C. Girolamo | CLO, SVP of Corp Dev | $480,873 | Mixed | 13 Jan 2022 | ||
| Peter G. Traber | Director | $446,078 | Mixed | 10 Jan 2022 | ||
| Mohammad Azab | Director | $246,573 | Mixed | 09 Jan 2026 | ||
| Steven M. Klosk | Director | $225,165 | Mixed | 09 Jan 2026 | ||
| Gregory B. Brown | Director | $224,798 | Mixed | 09 Jan 2026 | ||
| Cynthia Louise Flowers | Director | $224,298 | Mixed | 09 Jan 2026 | ||
| Heidi Henson | Director | $201,453 | Mixed | 09 Jan 2026 | ||
| Kristen K. Buck | EVP, R&D and CMO | $184,120 | Mixed | 09 Jan 2026 | ||
| Tariq Imam | SVP, Bus Dev, General Counsel | $71,073 | Mixed | 09 Jan 2026 | ||
| James Nisco | SVP, Fin/Treas, Chief Actg Off | $63,652 | Mixed | 09 Jan 2026 | ||
| David W. Slack | President & CBO, Director | $61,720 | Mixed | 09 Jan 2023 |
Recent insider transactions for LISATA THERAPEUTICS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David J. Mazzo | LSTA | Common Stock | Tax liability | -11.6% | -41,096 | 311,890 | 09 Jan 2026 | Direct | ||
| David J. Mazzo | LSTA | Common Stock | Award | 29.8% | 81,000 | 352,986 | 09 Jan 2026 | Direct | ||
| David J. Mazzo | LSTA | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 09 Jan 2026 | Direct | |||
| James Nisco | LSTA | Common Stock | Tax liability | -16.1% | -6,180 | 32,311 | 09 Jan 2026 | Direct | ||
| James Nisco | LSTA | Common Stock | Award | 63.8% | 15,000 | 38,491 | 09 Jan 2026 | Direct | ||
| James Nisco | LSTA | Stock Option (Right to Buy) | Award | 7,000 | 7,000 | 09 Jan 2026 | Direct | |||
| Tariq Imam | LSTA | Common Stock | Tax liability | -8.85% | -3,501 | 36,078 | 09 Jan 2026 | Direct | ||
| Tariq Imam | LSTA | Common Stock | Award | 61% | 15,000 | 39,579 | 09 Jan 2026 | Direct | ||
| Tariq Imam | LSTA | Stock Option (Right to Buy) | Award | 7,000 | 7,000 | 09 Jan 2026 | Direct | |||
| Kristen K. Buck | LSTA | Common Stock | Tax liability | -10.8% | -11,332 | 93,462 | 09 Jan 2026 | Direct | ||
| Kristen K. Buck | LSTA | Common Stock | Award | 31.3% | 25,000 | 104,794 | 09 Jan 2026 | Direct | ||
| Kristen K. Buck | LSTA | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 09 Jan 2026 | Direct | |||
| Steven M. Klosk | LSTA | Common Stock | Award | 46.6% | 30,456 | 95,815 | 09 Jan 2026 | Direct | ||
| Heidi Henson | LSTA | Common Stock | Award | 55.1% | 30,456 | 85,725 | 09 Jan 2026 | Direct | ||
| Cynthia Louise Flowers | LSTA | Common Stock | Award | 46.9% | 30,456 | 95,446 | 09 Jan 2026 | Direct | ||
| Gregory B. Brown | LSTA | Common Stock | Award | 46.7% | 30,456 | 95,659 | 09 Jan 2026 | Direct | ||
| Mohammad Azab | LSTA | Common Stock | Award | 40.9% | 30,456 | 104,925 | 09 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.